A Review of Emerging ARNI Data in HFrEF

Overview

Despite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.

Despite this evidence and the recommendation of clinical guidelines, ARNI therapy is not initiated in the majority of eligible patients. Evidence suggests a lack of understanding of a patient’s risk and also the benefit of life saving therapies by physicians is a primary cause of under-utilization.

Increased education is needed so clinicians fully understand the patient’s risk, as well as latest mechanistic and clinical data to ensure confidence in using newer therapies.

This educational program summarises new data covering ARNI therapy for heart failure with reduced ejection fraction (HFrEF) presented at the European Society of Cardiology (ESC) 2019 congress.

Target Audience

This programme is intended to educate:

  • Heart Failure Specialists
  • General Cardiologists

Learning Objectives

  • Review updated data of ARNI therapy for HFrEF present at the ESC 2019;

  • understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases);

  • interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data;

  • apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized; patients

  • Apply clinical and real-world evidence data for the treatment HFrEF with ARNI therapy. 

Disclosures

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

This activity has been supported by an unrestricted educational grant from Novartis.

R-CME Disclaimer / Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

Course summary
Available credit: 
  • 1.00 European Board for Accreditation in Cardiology (EBAC)
Course opens: 
10/23/2019
Course expires: 
07/31/2024
Cost:
£0.00
Rating: 
0

Course Directors

Prof Andrew Coats, University of Warwick

Prof Scott Solomon, Harvard Medical School, MA, US

Speakers

Prof Uwe Zeymer, Klinikum Ludwigshafen, DE

Prof James Januzzi, Harvard Medical School, MA, US

Prof Akshay Desai, Harvard Medical School, MA, US

Prof Rolf Wachter, Universität Leipzig, Leipzig, DE

Prof David Morrow, Harvard Medical School, MA, US

 

Please note that relevant faculty disclosures are included in the presentations.
This activity has been supported by an unrestricted educational grant from Novartis.
 

The event ‘A Review of Emerging ARNI Data in HFrEF’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

 

Available Credit

  • 1.00 European Board for Accreditation in Cardiology (EBAC)

Accreditation Period

Course opens: 
10/23/2019
Course expires: 
07/31/2024

Price

Cost:
£0.00
Please login or register to take this course.